Halozyme Therapeutics Past Earnings Performance
Past criteria checks 5/6
Halozyme Therapeutics has been growing earnings at an average annual rate of 33.9%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 32.4% per year. Halozyme Therapeutics's return on equity is 86.7%, and it has net margins of 41.4%.
Key information
33.9%
Earnings growth rate
35.2%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 32.4% |
| Return on equity | 86.7% |
| Net Margin | 41.4% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Halozyme Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 947 | 392 | 150 | 0 |
| 30 Jun 24 | 873 | 337 | 144 | 0 |
| 31 Mar 24 | 863 | 319 | 147 | 0 |
| 31 Dec 23 | 829 | 282 | 149 | 0 |
| 30 Sep 23 | 781 | 254 | 127 | 0 |
| 30 Jun 23 | 774 | 234 | 127 | 0 |
| 31 Mar 23 | 705 | 182 | 145 | 0 |
| 31 Dec 22 | 660 | 202 | 122 | 0 |
| 30 Sep 22 | 581 | 211 | 120 | 0 |
| 30 Jun 22 | 487 | 366 | 98 | 0 |
| 31 Mar 22 | 472 | 435 | 53 | 0 |
| 31 Dec 21 | 443 | 403 | 50 | 0 |
| 30 Sep 21 | 463 | 409 | 47 | 0 |
| 30 Jun 21 | 412 | 229 | 46 | 0 |
| 31 Mar 21 | 331 | 163 | 44 | 0 |
| 31 Dec 20 | 268 | 129 | 46 | 0 |
| 30 Sep 20 | 200 | 22 | 48 | 0 |
| 30 Jun 20 | 180 | -40 | 54 | 0 |
| 31 Mar 20 | 164 | -80 | 61 | 0 |
| 31 Dec 19 | 196 | -72 | 77 | 0 |
| 30 Sep 19 | 203 | -40 | 71 | 0 |
| 30 Jun 19 | 182 | -43 | 68 | 0 |
| 31 Mar 19 | 178 | -51 | 65 | 0 |
| 31 Dec 18 | 152 | -80 | 61 | 0 |
| 30 Sep 18 | 281 | 46 | 58 | 0 |
| 30 Jun 18 | 319 | 76 | 56 | 0 |
| 31 Mar 18 | 318 | 68 | 55 | 0 |
| 31 Dec 17 | 317 | 63 | 54 | 0 |
| 30 Sep 17 | 166 | -88 | 51 | 0 |
| 30 Jun 17 | 134 | -120 | 50 | 0 |
| 31 Mar 17 | 134 | -116 | 48 | 0 |
| 31 Dec 16 | 147 | -103 | 46 | 0 |
| 30 Sep 16 | 160 | -71 | 44 | 0 |
| 30 Jun 16 | 149 | -67 | 43 | 0 |
| 31 Mar 16 | 159 | -37 | 41 | 0 |
| 31 Dec 15 | 135 | -32 | 40 | 0 |
| 30 Sep 15 | 113 | -42 | 38 | 0 |
| 30 Jun 15 | 107 | -38 | 36 | 0 |
| 31 Mar 15 | 82 | -57 | 35 | 0 |
| 31 Dec 14 | 75 | -68 | 36 | 0 |
| 30 Sep 14 | 57 | -85 | 37 | 0 |
| 30 Jun 14 | 59 | -84 | 36 | 0 |
| 31 Mar 14 | 55 | -91 | 35 | 0 |
| 31 Dec 13 | 55 | -83 | 32 | 0 |
Quality Earnings: RV7 has high quality earnings.
Growing Profit Margin: RV7's current net profit margins (41.4%) are higher than last year (32.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RV7 has become profitable over the past 5 years, growing earnings by 33.9% per year.
Accelerating Growth: RV7's earnings growth over the past year (54.6%) exceeds its 5-year average (33.9% per year).
Earnings vs Industry: RV7 earnings growth over the past year (54.6%) exceeded the Biotechs industry -18.2%.
Return on Equity
High ROE: Whilst RV7's Return on Equity (86.69%) is outstanding, this metric is skewed due to their high level of debt.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 10:06 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Halozyme Therapeutics, Inc. is covered by 34 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ishan Majumdar | Baptista Research |
| James Birchenough | Barclays |
| Robert Wasserman | Benchmark Company |